Johnson & Johnson (NYSE:JNJ) Stake Raised by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 156,567 shares of the company’s stock after purchasing an additional 1,335 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Johnson & Johnson were worth $25,577,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of JNJ. RKL Wealth Management LLC boosted its stake in Johnson & Johnson by 2.1% during the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after purchasing an additional 1,010 shares in the last quarter. Geller Advisors LLC boosted its stake in Johnson & Johnson by 7.5% during the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after buying an additional 648 shares in the last quarter. Simon Quick Advisors LLC raised its position in Johnson & Johnson by 296.9% in the second quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock worth $1,495,000 after acquiring an additional 6,537 shares in the last quarter. Lokken Investment Group LLC lifted its holdings in Johnson & Johnson by 1.6% in the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after acquiring an additional 201 shares during the last quarter. Finally, Keebeck Alpha LP grew its stake in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock worth $788,000 after purchasing an additional 525 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Sanford C. Bernstein reduced their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James decreased their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Atlantic Securities reduced their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. SVB Leerink dropped their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $181.75.

Insiders Place Their Bets

In other news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock valued at $40,960,735 over the last three months. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The business’s 50-day moving average price is $175.98 and its two-hundred day moving average price is $171.06. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.23 by $0.12. The business had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.13 EPS. Analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.